Saturday 17 October 2026
Export AFMDQ’s income statement to Excel — free account
Affimed N.V.
AFMDQ Healthcare Biotechnology
Affimed N.V.’s revenue for fiscal 2023 (year ended December 2023) was $9.0 million, down 79.4% from fiscal 2022.
0.00
0.00
NaN
Follow AFMDQ
| Sep '24 | Jun '24 | Mar '24 | Dec '23 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
1 | 1 | 1 | 1 |
+8 more TTM periods Free account |
| (148.64%) | (123.54%) | (113.38%) | (102.52%) | ||
| (86.68%) | (83.99%) | (78.75%) | (72.47%) | ||
ROIC |
(13,558.83%) | (1,798.06%) | (2,837.67%) | 0.00% | |
Return on Tangible Assets |
(386.35%) | (258.09%) | (210.55%) | (167.66%) | |
Average Days of Receivables |
1,882.86 | 766.06 | 558.62 | 234.97 | |
Free Cash Flow per Share |
(5.18) | (6.16) | (7.50) | (8.26) | |
Free Cash Flow |
(83.32) | (94.23) | (113.55) | (123.38) | |
Capital Expenditures |
0.29 | (4.05) | (4.03) | (4.04) | |
| Other line items | |||||
Cash ROIC |
(150.95%) | (119.08%) | (103.72%) | (79.80%) | |
Accounts Receivable Turnover |
0.25 | 0.69 | 0.98 | 2.08 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
— | — | — | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
6,258.03% | 2,483.66% | 2,049.46% | 1,147.53% | |
Selling, General and Administrative Expense of Revenue |
2,127.15% | 740.29% | 565.28% | 298.19% | |
Share Based Compensation of Revenue |
401.34% | 174.68% | 186.52% | 129.48% | |
Operating CF/Net income |
1.10 | 1.05 | 1.08 | 1.04 | |
Depreciation/Fixed assets |
1.52 | 1.58 | 1.48 | 0.36 | |
Capex/Depreciation |
0.08 | (1.02) | (1.05) | (2.13) | |
Revenue per Share |
0.06 | 0.19 | 0.28 | 0.60 | |
Operating CF per Share |
(5.19) | (5.89) | (7.24) | (7.99) | |
Capex per Share |
0.02 | (0.26) | (0.27) | (0.27) | |
Capex to Sales |
(0.29) | 1.38 | 0.94 | 0.45 |
Columns are period end dates